Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00251
|
|||||
| Drug Name |
Docetaxel
|
|||||
| Synonyms |
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; ANX-514; Docetaxel (INN); Docetaxel 114977-28-5; Docetaxel anhydrous; Docetaxel, Trihydrate; EmDOC; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; N-debenzoyl-N-Boc-10-deacetyl taxol; RP-56976; SDP-014; TXL; Taxotere; Taxotere (TN); Taxotere(R); XRP-6976L
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Breast cancer [ICD11: 2C60-2C6Z] | Approved | [1] | |||
| Lung cancer [ICD11: 2C25] | Approved | [1] | ||||
| Prostate cancer [ICD11: 2C82] | Approved | [1] | ||||
| Gastric cancer [ICD11: 2B72] | Approved | [1] | ||||
| Head and neck cancer [ICD11: 2B60-2B6E] | Approved | [1] | ||||
| Ovarian cancer [ICD11: 2C73] | Approved | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C43H53NO14
|
|||||
| Canonical SMILES |
CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
|
|||||
| InChI |
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
|
|||||
| InChIKey |
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
|
|||||
| CAS Number |
CAS 114977-28-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 807.9 | Topological Polar Surface Area | 224 | ||
| Heavy Atom Count | 58 | Rotatable Bond Count | 13 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 14 | |||
| XLogP |
1.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10249812
, 103172104
, 104418276
, 117664410
, 117682515
, 12014196
, 124950708
, 126606827
, 126630894
, 126657365
, 13410
, 134337881
, 136340291
, 136375539
, 14791415
, 14815974
, 17424977
, 24845209
, 26683886
, 46225079
, 46506766
, 494081
, 53790583
, 56310805
, 56310954
, 56311107
, 56311313
, 56311574
, 56312625
, 56312880
, 56312940
, 56312941
, 56313207
, 56313989
, 56314033
, 56314070
, 56314178
, 56314280
, 57346703
, 78743198
, 7890914
, 7979114
, 81044598
, 822539
, 833094
, 87678200
, 92308884
, 92711403
, 96024562
, 99319097
|
|||||
| ChEBI ID |
ChEBI:4672
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [3] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [4] | ||
| MRP7 | Transporter Info | Multidrug resistance-associated protein 7 | Substrate | [5] | ||
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [6] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [7] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [8] | ||
| TAPL | Transporter Info | TAP-like protein | Substrate | [9] | ||
| References | ||||||
| 1 | Docetaxel was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32. | |||||
| 3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 4 | Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36. | |||||
| 5 | Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67. | |||||
| 6 | FDA Drug Development and Drug Interactions | |||||
| 7 | Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9. | |||||
| 8 | Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6. | |||||
| 9 | RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.